Ab­b­Vie hands Voy­ager a mega-bil­lions gene ther­a­py deal, with $310M in near-term cash

Gene ther­a­py com­pa­ny Voy­ager Ther­a­peu­tics has kicked off 2019 in style. Af­ter forg­ing an up to $1.8 bil­lion pact with Neu­ro­crine last month, the Parkin­son’s drug de­vel­op­er ex­pand­ed its part­ner­ship with Ab­b­Vie on Fri­day, days fol­low­ing the an­niver­sary of their orig­i­nal pact.

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER